Clofazimine
DefinitionThis section has been translated automatically.
Spectrum of actionThis section has been translated automatically.
Mycobacterium leprae, some atypical mycobacteria.
IndicationThis section has been translated automatically.
Dosage and method of useThis section has been translated automatically.
50-300 mg/day p.o.
Undesirable effectsThis section has been translated automatically.
Red to brown-black discoloration of the skin, especially in light-exposed areas, discoloration of hair, conjunctiva, sweat, sputum, stool and urine, ichthyosis, photosensitivity, allergic reactions, vomiting, abdominal pain, diarrhea, loss of appetite.
PreparationsThis section has been translated automatically.
Lamprene (International Pharmacy)
Note(s)This section has been translated automatically.
- The preparation Lamprene and the active substance clofazimine have meanwhile been supplied by the manufacturer Novartis to the WHO for the free treatment of leprosy. An international pharmacy in Zurich (Victoria Pharmacy Zurich) has been commissioned with the exclusive distribution of Lamprene, solely to ensure that off-label use is still possible for the treatment of skin diseases outside leprosy. For this purpose, it is necessary to order the preparation Lamprene directly from the Victoria Pharmacy in Zurich. The manufacturer Novartis has waived financial compensation by dispensing the drug for free distribution, so that no drug costs are actually incurred. On the part of the cost-bearer (statutory health insurance companies), only the expenses of Victoria Pharmacy for the further distribution of the drug on medical prescription in the case of off-label use indications (import surcharges etc.) are to be borne.
Remember! If clofazimine is used outside the approved indications (off-label use), it is recommended that both the off-label use and the imported drug status of clofazimine are covered by health insurance before treatment begins.